Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07321332

Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07321332 Descriptor: (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 Authors: Zeng, P, Zhang, J, Li, J. Deposit date: 2022-12-27 Release date: 2023-12-27 Last modified: 2025-07-09 Method: X-RAY DIFFRACTION (1.63 Å) Cite: Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants. Biochemistry, 62, 2023

严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）主蛋白酶G15S突变体与PF07321332的复合物晶体结构。描述：配体为(1R,2S,5S)-N-{(1E,2S)-1-亚氨基-3-[(3S)-2-氧代吡咯烷-3-基]丙-2-基}-6,6-二甲基-3-[3-甲基-N-(三氟乙酰基)-L-缬氨酰]-3-氮杂双环[3.1.0]己烷-2-甲酰胺，靶蛋白为3C样蛋白酶（3C-like proteinase）nsp5。作者：Zeng, P、Zhang, J、Li, J。存档日期：2022-12-27；发布日期：2023-12-27；最后修改日期：2025-07-09。实验方法：X射线衍射（分辨率1.63埃）。引用文献：《评估奈玛特韦对SARS-CoV-2变异株主蛋白酶突变体的抑制活性》，《生物化学》，第62卷，2023年。